Standout Papers
- The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease (2014)
- Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients (2013)
Citation Impact
Citing Papers
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
2008
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
2003
Reductions in 28-Day Mortality Following Hospital Admission for Upper Gastrointestinal Hemorrhage
2011 Standout
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
2010
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
2009
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
2009
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
2015
Oxidative stress, aging, and diseases
2018 Standout
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
2010 Standout
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
2012
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
2009
Transfusion Strategies for Acute Upper Gastrointestinal Bleeding
2013 Standout
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Variability in Individual Responsiveness to Clopidogrel
2007
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer
2009
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
2008
New Antithrombotic Drugs
2012
Obesity and Antiplatelets-Does One Size Fit All?
2015
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
Relation of Genetic Polymorphisms in the Cytochrome P450 Gene With Clopidogrel Resistance After Drug-Eluting Stent Implantation in Koreans
2009
Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
2012
Pharmacokinetics and safety review of tazarotene
1998
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome
2009
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
2009
Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis
2004
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
2009
Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
2011
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial
2003
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
2010
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study
2017
Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy
2009
Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
2009
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration
2010
Antiplatelet Drugs
2012
Pharmacology of Antiplatelet Agents
2013
Human recombinant activated protein C for severe sepsis
2012
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
2010
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
2010
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
2010
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention
2009
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
2008
Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
2007
Clopidogrel–Drug Interactions
2011
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society
2009
Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability
2010
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis
2015
Sickle-cell disease
2010 Standout
Aspirin and Antiplatelet Agent Resistance
2010
Platelet function normalization after a prasugrel loading‐dose: time‐dependent effect of platelet supplementation
2012
Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management
2014
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
2008
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
2018
Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis
2010
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention
2008
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent Placement
2010
Osteoarthritis
2019 Standout
High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials
2012
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention
2012
Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity
2010
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response
2012
Extracellular histones are major mediators of death in sepsis
2009 Standout
Cutaneous Squamous-Cell Carcinoma
2001 Standout
Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
2008
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
2011
International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding
2010 Standout
Rapid Diagnostic Assay for Intact Influenza Virus Using a High Affinity Hemagglutinin Binding Protein
2017 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
2013
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
2009
Guidelines for the Primary Prevention of Stroke
2014 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association
2016
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
2019 Standout
Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan
2009
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
2009
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations
2012
Aspirin and Antiplatelet Agent Resistance
2010
Point of Care Diagnostics: Status and Future
2011
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
2007
Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications
2013
Prasugrel
2009
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)
2011
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
Part 8: Post–Cardiac Arrest Care
2015 Standout
Prasugrel
2009
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Iron-Deficiency Anemia
2015 Standout
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
2009
Fourth universal definition of myocardial infarction (2018)
2018 Standout
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
2008
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
2009
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
2010
Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency
2006
Response to Letter by van Werkum: Proton pump inhibitors and clopidogrel: a difficult dilemma
2009
ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2012
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of David S. Small being referenced
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
2006
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel
2007
QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study
2007
Metabolic Deesterification of Tazarotene in Human Blood and Rat and HumanLiver Microsomes
1997
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38
2009
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
2009
Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects
2009
Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy
2011
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
2008
Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients
2013 StandoutNobel
Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel
2008
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients
2012
The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data
2011
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
2008
Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects
2006
Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent
2010
Prasugrel in Children With Sickle Cell Disease
2014
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
2007
The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects
2006
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
2008
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants
2011
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
2008
Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel
2010
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
2008
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity
2012
Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin
2011
Pharmacokinetic‐pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
2002
Abstract 4001: Relationship between Exposure to the Prasugrel Active Metabolite with TIMI Major/Minor Bleeding in TRITON-TIMI 38
2008